id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10176 R37260 |
Blotière (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Cleft palate | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
5.87 [0.83;41.78] C excluded (control group) |
2/512 2/2,997 | 4 | 512 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9766 R34910 |
Blotière (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2019 | Cleft palate | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 6.30 [0.80;22.90] | 2/512 1,178/1,875,733 | 1,180 | 512 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9648 R34333 |
Viinikainen (Carbamazepine) (Controls unexposed, sick) a, 2006 | Cleft palate | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 2.19 [0.09;54.89] C | 1/72 0/52 | 1 | 72 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 5.03 [1.14;22.26] | 1,181 | 584 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Controls unexposed NOS) (Mixed indications; 2: Carbamazepine) (Controls unexposed, sick) ;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 10176